Aura Biosciences has closed a $30 million Series C round with funding from new investors like Arix Bioscience and Lundbeckfonden Ventures, as well as existing investors, including the estate of former-Genzyme CEO Henri Termeer, who died earlier this year.
The privately-held biotech is developing a light-activated nanoparticle therapy for patients with ocular melanoma. Aura said it plans to use its newly-acquired funds to expand infrastructure for its Phase Ib/II clinical trial.
Get the full story at our sister site, Drug Delivery Business News.
The post Aura Biosciences raises $30m for nanoparticle cancer treatment appeared first on MassDevice.
from MassDevice http://ift.tt/2BKekoR
Cap comentari:
Publica un comentari a l'entrada